Medicenna Therapeutics Corp (MDNA) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.799x

Based on the latest financial reports, Medicenna Therapeutics Corp (MDNA) has a cash flow conversion efficiency ratio of -0.799x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-4.96 Million ≈ $-3.59 Million USD) by net assets (CA$6.21 Million ≈ $4.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Medicenna Therapeutics Corp to measure how much of total assets are equity-financed.

Medicenna Therapeutics Corp - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Medicenna Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MDNA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Medicenna Therapeutics Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Medicenna Therapeutics Corp ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Medivir AB ST:MVIR	N/A
SCI Electric Public Company Limited BK:SCI	0.031x
Scope Industries Bhd KLSE:0028	0.057x
Lodzia TA:LODZ	0.018x
SeaTwirl AB ST:STW	0.567x
QMINES LTD F:81V	N/A
DAP Corporation KQ:066900	0.040x
Brill Shoe Industries Ltd TA:BRIL	0.005x

Annual Cash Flow Conversion Efficiency for Medicenna Therapeutics Corp (2014–2025)

The table below shows the annual cash flow conversion efficiency of Medicenna Therapeutics Corp from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see MDNA company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	CA$19.09 Million ≈ $13.81 Million	CA$-16.49 Million ≈ $-11.93 Million	-0.864x	+72.43%
2024-03-31	CA$5.19 Million ≈ $3.76 Million	CA$-16.26 Million ≈ $-11.76 Million	-3.132x	-629.72%
2023-03-31	CA$29.49 Million ≈ $21.33 Million	CA$-12.66 Million ≈ $-9.16 Million	-0.429x	+62.08%
2022-03-31	CA$20.84 Million ≈ $15.07 Million	CA$-23.58 Million ≈ $-17.06 Million	-1.132x	-182.01%
2021-03-31	CA$38.15 Million ≈ $27.59 Million	CA$-15.31 Million ≈ $-11.08 Million	-0.401x	-62.04%
2020-03-31	CA$36.15 Million ≈ $26.15 Million	CA$-8.95 Million ≈ $-6.48 Million	-0.248x	+91.94%
2019-03-31	CA$2.62 Million ≈ $1.89 Million	CA$-8.04 Million ≈ $-5.81 Million	-3.072x	+34.41%
2018-03-31	CA$2.16 Million ≈ $1.56 Million	CA$-10.12 Million ≈ $-7.32 Million	-4.683x	-326.75%
2017-03-31	CA$6.66 Million ≈ $4.82 Million	CA$-7.31 Million ≈ $-5.28 Million	-1.097x	+4.17%
2016-03-31	CA$2.24 Million ≈ $1.62 Million	CA$-2.57 Million ≈ $-1.86 Million	-1.145x	-102.51%
2015-03-31	CA$-19.30K ≈ $-13.96K	CA$-880.32K ≈ $-636.81K	45.603x	+1865.98%
2014-03-31	CA$-267.05K ≈ $-193.18K	CA$-619.44K ≈ $-448.09K	2.320x	--

About Medicenna Therapeutics Corp

TO:MDNA Canada Biotechnology

Market Cap

$21.72 Million

CA$30.03 Million CAD

Market Cap Rank

#24791 Global

#954 in Canada

Share Price

CA$0.36

Change (1 day)

+2.86%

52-Week Range

CA$0.35 - CA$1.64

All Time High

CA$7.00